尿中膀胱癌标志物的敏感性和特异性——就这么简单吗?

IF 1 4区 医学 Q4 ONCOLOGY Bladder Cancer Pub Date : 2022-03-11 eCollection Date: 2022-01-01 DOI:10.3233/BLC-211602
Florian Roghmann, Peter J Goebell, Lars Dyrskjøt, Bas W G van Rhijn, Heiko U Käfferlein, Oliver Hakenberg, Arnulf Stenzl, Maximilian Burger, Beate Pesch, Natalya Benderska-Söder, Bernd J Schmitz-Dräger
{"title":"尿中膀胱癌标志物的敏感性和特异性——就这么简单吗?","authors":"Florian Roghmann, Peter J Goebell, Lars Dyrskjøt, Bas W G van Rhijn, Heiko U Käfferlein, Oliver Hakenberg, Arnulf Stenzl, Maximilian Burger, Beate Pesch, Natalya Benderska-Söder, Bernd J Schmitz-Dräger","doi":"10.3233/BLC-211602","DOIUrl":null,"url":null,"abstract":"<p><p>Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181706/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?\",\"authors\":\"Florian Roghmann, Peter J Goebell, Lars Dyrskjøt, Bas W G van Rhijn, Heiko U Käfferlein, Oliver Hakenberg, Arnulf Stenzl, Maximilian Burger, Beate Pesch, Natalya Benderska-Söder, Bernd J Schmitz-Dräger\",\"doi\":\"10.3233/BLC-211602\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.</p>\",\"PeriodicalId\":54217,\"journal\":{\"name\":\"Bladder Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-03-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181706/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bladder Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3233/BLC-211602\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/BLC-211602","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

标志物研究,特别是过去三十年的膀胱肿瘤标志物研究,在人力(更不用说花在审稿和编辑工作上的时间)和财政资源方面消耗了巨大的科学资源,最终产生了大量的手稿,而不影响临床决策。由于缺乏一级证据,目前的指南不建议使用标记物,这一事实也反映了这一点。尽管我们认识到存在的问题和障碍,但这篇评论的作者认为,是时候放弃目前的程序,转而进行前瞻性试验设计,将标记结果应用于临床决策。我们的想法和关注总结在这条评论中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?

Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bladder Cancer
Bladder Cancer Medicine-Urology
CiteScore
1.60
自引率
0.00%
发文量
35
期刊介绍: Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.
期刊最新文献
Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial Urologists and Advanced Practice Providers Evaluating Hematuria. Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1